Loading clinical trials...
Loading clinical trials...
Developing Oral LT3 Therapy For Heart Failure With Reduced Ejection Fraction
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction (HFrEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.
The overall goal is to determine the safety, feasibility, and preliminary efficacy of administering oral LT3 therapy in the study population of participants with Heart Failure with reduced ejection fraction (HFrEF). The study will consist of two treatment periods - each treatment period will be approximately 8 weeks in duration, with weekly titration of study drug for 4 weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to the other arm (placebo or drug). LT3 will be titrated to T3 levels.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
PennMedicine
Philadelphia, Pennsylvania, United States
Start Date
February 11, 2020
Primary Completion Date
October 31, 2023
Completion Date
October 31, 2023
Last Updated
December 24, 2024
28
ACTUAL participants
Liothyronine
DRUG
Placebo
OTHER
Lead Sponsor
University of Pennsylvania
Collaborators
NCT06964464
NCT04180696
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions